Anti-myostatin / anti-GDF8 antibody

Trevogrumab

A myostatin antibody being tested specifically to improve the quality of GLP-1 weight loss.

Evidence Maturity · M3 - Clinical Investigational - Phase 2
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

Trevogrumab is one of the clearest examples of the new 'muscle race' in obesity medicine.

Signal interpretation: Trevogrumab may matter less because it causes dramatic scale-weight loss and more because it could change the composition of GLP-1-associated weight loss. These are distinct questions from total weight loss.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

COURAGE weight-loss phase

Population
Adults with obesity; sponsor table reports 599 participants across four analyzed groups.
Doses and administration studied
Trevogrumab 200 or 400 mg with semaglutide 2.4 mg; triplet arm also included garetosmab 10 mg/kg. Trevogrumab is subcutaneous and garetosmab intravenous; the cited release does not specify their complete administration intervals.
Duration
26-week weight-loss analysis; a separate maintenance period follows
Reported finding / status
Sponsor reported reduced lean-mass loss with combinations versus semaglutide alone.
Interpretation and limitations
Sponsor-reported analysis; do not infer an administration schedule absent from the source. Triplet tolerability/discontinuation concerns require separate consideration.

Source tier E · Read the original study or record

Outcome Evidence Strength

Weight change2/5
Fat-mass change2/5
Lean-mass change2/5
Strength / function benefit0/5

Weight, fat and lean: sponsor-reported randomized findings. Function: no established benefit in this report.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • In Regeneron's 26-week COURAGE analysis, about 33% of semaglutide-associated weight loss was lean mass in the semaglutide-alone arm.
  • Adding trevogrumab reduced lean-mass loss by roughly half while increasing fat loss in the reported analysis.
  • COURAGE directly measures lean mass, fat mass and body weight.

What is not established?

  • The headline findings are sponsor-reported and should not be treated as equivalent to a peer-reviewed pivotal trial.
  • Long-term function, durability, and safety require additional evidence.
  • The triplet regimen including garetosmab had more tolerability problems and discontinuations in the reported analysis.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier E: Sponsor-reported Phase 2 results
Complete 26-week COURAGE results
Source tier D: Registered clinical trial
COURAGE trial record
Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.